Ar­gos’ PhI­II for its per­son­al­ized can­cer vac­cine im­plodes dur­ing an in­ter­im analy­sis

Ar­gos Ther­a­peu­tics’ $ARGS Phase III study of its per­son­al­ized can­cer vac­cine ro­ca­pulden­cel-T has end­ed in dis­as­ter. Its in­de­pen­dent mon­i­tor­ing com­mit­tee con­clud­ed in an in­ter­im analy­sis that the late-stage tri­al for metasta­t­ic re­nal cell car­ci­no­ma was head­ed to a near cer­tain fail­ure, call­ing for an end to the study.

Ar­gos treat­ment is de­signed to cap­ture the anti­gens spe­cif­ic to a pa­tients’ tu­mor cells, ramp­ing up an im­mune re­sponse to wipe out those can­cer cells. In­ves­ti­ga­tors com­bined their drug with Su­tent (suni­tinib) and com­pared it to stan­dard of care.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN